Analyst Price Targets — SPRB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 23, 2025 11:26 am | — | Oppenheimer | $283.00 | $82.82 | TheFly | Spruce Biosciences initiated with an Outperform at Oppenheimer |
| November 11, 2025 10:52 am | — | JMP Securities | $259.00 | $115.61 | TheFly | Spruce Biosciences price target raised to $259 from $254 at Citizens JMP |
| October 28, 2025 8:41 am | — | JMP Securities | $254.00 | $123.02 | TheFly | Spruce Biosciences upgraded to Outperform from Market Perform at Citizens JMP |
| October 21, 2025 6:38 pm | — | Leerink Partners | $160.00 | $134.00 | StreetInsider | Spruce Biosciences, Inc. (SPRB) PT Raised to $160 at Leerink PartnersMember Login |
Latest News for SPRB
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate updates. “2025 was a very productive year, and our team continues to execute…
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Dale Hooks as Chief Commercial Officer. Mr. Hooks joins the company with nearly 35 years of pharmaceutical marketing and sales…
Executives from Spruce Biosciences (NASDAQ: SPRB) outlined regulatory plans, clinical data highlights, and commercial considerations for the company's lead program in Sanfilippo syndrome type B (MPS IIIB) during a fireside chat at Oppenheimer's 36th Annual Healthcare and Life Sciences Conference. Program overview and development history Chief Executive Officer Dr. Javier Szwarcberg discussed Spruce's enzyme…
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at two upcoming investor conferences taking place in March. Leerink Global…
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the successful completion of Type B meetings with the U.S. Food and Drug Administration (FDA or the Agency) regarding its planned upcoming biologics…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SPRB.
U.S. House Trading
No House trades found for SPRB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.